Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price8,944.50 INR
Ethical score0.0/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Accumulation8,944.50+0.0% to today ✓
2026-08-05Read Markup8,358.50+7.0% to today ✓
2026-07-21Read Accumulation8,358.50+7.0% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Apollo Hospitals holds its Accumulation at $8,944.50. Consolidating, no directional conviction, held for 4 days.
As held on the ledger · 2026-09-18
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 4 days
Price at the screen
$8,944.50
Valuation
0.00 trailing · 0.00 forward price to earnings
Values screen
FAIL· score 0.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
38.26%
Below 33%
Interest-bearing debt is 38.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
5.67%
Below 33%
Cash held in interest-bearing accounts and securities is 5.7% of assets, under the one-third limit.
Pass
Receivables
19.35%
Below 49%
Money owed to the company is 19.4% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Apollo Hospitals's business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
On our numbers, the price already runs ahead of the business.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
APOLLOHOSP.NS trades on NSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138.
2026-09-12Markup$8,358.50+0.0%Entry 13
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138.
2026-08-12Markup$8,358.50+0.0%Entry 12
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-11Markup$8,358.50+0.0%Entry 11
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-09Markup$8,358.50+0.0%Entry 10
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-08Markup$8,358.50+0.0%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-07Markup$8,358.50+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-06Markup$8,358.50+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-05Markup · changed$8,358.50+0.0%Entry 6
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Accumulation$8,358.50+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (28 analysts) rates it strong buy, with a mean price target of $9138.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.